HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and raises the price target from $6 to $7.
August 14, 2023 | 10:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spero Therapeutics' price target has been raised from $6 to $7 by HC Wainwright & Co., maintaining a 'Buy' rating.
The news of a price target increase and maintained 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence in investors and could lead to a short-term increase in Spero Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100